Mikael Mattsson's research while affiliated with Lund University and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (2)
Antibody-based microarrays are a rapidly evolving affinity-proteomic methodology that recently has shown great promise in clinical applications. The resolution of these proteomic analyses is, however, directly related to the number of data-points, i.e. antibodies, included on the array. Currently, this is a key bottleneck because of limited availab...
Citations
... Of these, 379 of the scFv antibodies were directed against 161 (mainly immunoregulatory) antigens. The remaining 15 scFv antibodies were directed against 15 short amino acid motifs (4−6 amino acids long), denoted CIMS antibodies 25 (Supporting Information Table S2). For some analytes, more than one scFv antibody clone (n = 2−9) targeting different epitopes was chosen to minimize the risk of impaired antibody activity followed by epitope masking during the sample labeling process. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/885380572266498-1588102586502_Q64/Niclas-Olsson-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/273573545771038-1442236424722_Q64/Christer-Wingren.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/287174198087680-1445479072168_Q64/Peter-James-9.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/277064344195074-1443068695168_Q64/Carl-Borrebaeck.jpg)
